Is Novavax About to Achieve Warp Speed in the Coronavirus Vaccine Race?
With 11 coronavirus vaccine candidates in phase 3 trials and 49 in earlier stages, it can be hard for laypeople to estimate which has the best long-term potential. So much attention has been focused on finding the company with the first approved candidate that many investors have lost sight of the ingredients that typically produce multibagger stock gains.
While large-cap companies with dozens of drugs in their portfolios -- like Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) -- will benefit if they produce a successful vaccine, the smaller companies are in the best position to see their shares double, triple, or do even better. By aligning with large global organizations, receiving funding that significantly increases the size of their businesses, and revolutionizing approaches to treatment, smaller vaccine makers can radically accelerate their growth. For investors seeking to ride this opportunity, Novavax (NASDAQ: NVAX) fits the bill.
Image source: Getty Images.
Source Fool.com
